CN107174654A - The new application of interleukin 12 - Google Patents
The new application of interleukin 12 Download PDFInfo
- Publication number
- CN107174654A CN107174654A CN201710138386.6A CN201710138386A CN107174654A CN 107174654 A CN107174654 A CN 107174654A CN 201710138386 A CN201710138386 A CN 201710138386A CN 107174654 A CN107174654 A CN 107174654A
- Authority
- CN
- China
- Prior art keywords
- interleukin
- application
- toll
- new application
- hepatic metastases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
Abstract
The invention discloses a kind of new application of interleukin 12, it is characterized in that, interleukin 12 treats the application of the anti-hepatic metastases medicine of colorectal cancer as preparing；It is intended to widen the application of interleukin 12, while starting and enhancing inherent immunity and Acquired immune response, the cancer cell of residual is removed in time, reaches that anti-rotation is moved, reduce the purpose of rectal cancer recurrence.
Description
Technical field
The invention discloses a kind of novel drugs for treating colorectal cancer hepatic metastases, specifically, open interleukin 12
With medicine of the Toll-like receptor activator-flagellin as treatment colorectal cancer hepatic metastases.
Background technology
The morbidity and mortality of colorectal cancer are raised year by year in China, leap to malignant tumour the 3rd.Transfer and relapse is
Patients with Colorectal Cancer main causes of death, and hepatic metastases is more prominent.Operation is still effective therapeutic modality of colorectal cancer,
But operation can not still be effected a radical cure, and the rate of transform is very high, there is half patient's liver metastasis, wherein in first visit liver has occurred for 25% patient
Transfer, 25% patient in Post operation still can liver metastasis, therefore prevention hepatic metastases, as improve colorectal cancer prognosis key
Factor.The invention discloses a kind of new method for controlling and preventing the anti-hepatic metastases of post operative colo-rectal cancer, by starting inherent immunity
And Acquired immune response, the cancer cell of Postoperative Residual is removed in time, is eliminated in bud, so as to control tumour
Transfer.
The content of the invention
In view of the above-mentioned problems, resisting it is an object of the invention to provide interleukin 12 as treatment colorectal cancer is prepared
The application of hepatic metastases medicine, widens the application of interleukin 12, while starting and enhancing inherent immunity and acquired exempting from
Epidemic disease response, removes the cancer cell of residual in time, reaches that anti-rotation is moved, reduces the purpose of recurrence.
In order to solve the above technical problems, the technical scheme that the present invention is provided is such：
A kind of new application of interleukin 12, described interleukin 12 is used as the preparation treatment anti-liver of colorectal cancer
The application of diversion medicaments.
Further, a kind of new application of above-mentioned interleukin 12, the interleukin 12 is combined
Toll-like receptor activator-flagellin treats the application of the anti-hepatic metastases medicine of colorectal cancer as preparing.
Further, the new application of above-mentioned a kind of interleukin 12, it is characterised in that described leucocyte is situated between
Plain -12 dosage are 3-30 μ g.
Compared with prior art, provided by the present invention for the novel drugs of the treatment anti-hepatic metastases of colorectal cancer, in Colon and rectum
Cancer II, III phase patient swash while Post operation is in chemotherapy or radiotherapy using interleukin 12 3-30 μ g and Toll-like receptor
Agent-flagellin living, can start and strengthen inherent immunity and Acquired immune response, and the cancer cell of residual is removed in time, is reached
Anti-rotation is moved, and reduces the purpose of recurrence.
Embodiment
With reference to embodiment, the claim to the present invention is described in further detail, but is not constituted pair
Any limitation of the present invention, the modification of any limited number of time made in the claims in the present invention protection domain, still in the present invention
Claims within.
Embodiment 1
Experiment in vitro：RhIL-12(p70) combines Toll-like receptor activator, has to various human tumor cells
Detail suppresses growth.
Experimental method：Using lymph layering liquid separation human peripheral blood single nucleus cell, be separately added into physiological saline, 10~
100ng/ml IL-12,1~10ug Toll-like receptors activator, 10~100ng/ml IL-12 combines 1~10ug Toll
Sample receptor activators, after cultivating 12 hours, add various tumour cells, are detected after cultivating 12 hours.
Experimental result：IL-12 and Toll-like receptor activator can be remarkably reinforced PMNC to Ec109,
The lethal effect of SPC-A1, A549, NCL-H446,95-D, HS-746T, Hos, A-204,769-P tumor cell line, but IL-12
Joint Toll-like receptor activator lethal effect is most strong, is 260 times of saline control group, is IL-12 and Toll-like receptor
20~35 times when activator is alone.
Embodiment 2
In vivo studies：Mouse species experiment shows that rhIL-12 joint Toll-like receptor activator has to mouse Colon and rectum
The anti-hepatic metastases effect of cancer model.
Experimental method：From C57 mouse 36, it is divided into 4 groups, every group 9.Every mouse back subcutaneous vaccination SW480 is thin
Born of the same parents 5 × 106Individual cell, after being inoculated with 3 days, starts to give physiological saline, IL-12, Toll-like receptor activator, IL-12 connection respectively
Toll-like receptor activator is closed, is administered once within every 2 days, successive administration puts to death mouse after 2 weeks, takes liver section inspection, calculates hair
The number of cases of raw hepatic metastases.
Experimental result：There are 6 equal liver metastasis in physiological saline group dead 2, remaining 7；2 generations of IL-12 groups
Hepatic metastases；3 liver metastasis of Toll-like receptor activator group；IL-12 joint Toll-like receptor activator groups do not occur
Hepatic metastases.Illustrate that IL-12 joint Toll-like receptor activator can substantially suppress the generation of colorectal cancer hepatic metastases.
Above-described is only presently preferred embodiments of the present invention, all timess made in the range of the spirit and principles in the present invention
What modifications, equivalent substitutions and improvements etc., should be included in the scope of the protection.
Claims (3)
1. a kind of new application of interleukin 12, it is characterised in that described interleukin 12 is tied as treatment is prepared
The application of the anti-hepatic metastases medicine of the carcinoma of the rectum.
2. the new application of a kind of interleukin 12 according to claim 1, it is characterised in that described uses leucocyte
The application that the joint Toll-like receptor of interleukin -12 activator-flagellin treats the anti-hepatic metastases medicine of colorectal cancer as preparing.
3. a kind of new application of interleukin 12 according to claim 1 or 2, it is characterised in that described leucocyte
The dosage of interleukin -12 is 3-30 μ g.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610136958 | 2016-03-10 | ||
| CN2016101369582 | 2016-03-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107174654A true CN107174654A (en) | 2017-09-19 |
Family
ID=59830663
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710138386.6A Pending CN107174654A (en) | 2016-03-10 | 2017-03-09 | The new application of interleukin 12 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107174654A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101394865A (en) * | 2005-12-01 | 2009-03-25 | 都柏林伊丽莎白女皇神学院院长、研究员及专家协会 | Compositions and methods relating to treatment of cancer and infectious diseases |
| JP2009155221A (en) * | 2007-12-25 | 2009-07-16 | Yakult Honsha Co Ltd | Interleukin 12 production promoter |
| WO2016014899A1 (en) * | 2014-07-25 | 2016-01-28 | Cleveland Biolabs, Inc. | Flagellin derivatives and uses |
-
2017
- 2017-03-09 CN CN201710138386.6A patent/CN107174654A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101394865A (en) * | 2005-12-01 | 2009-03-25 | 都柏林伊丽莎白女皇神学院院长、研究员及专家协会 | Compositions and methods relating to treatment of cancer and infectious diseases |
| JP2009155221A (en) * | 2007-12-25 | 2009-07-16 | Yakult Honsha Co Ltd | Interleukin 12 production promoter |
| WO2016014899A1 (en) * | 2014-07-25 | 2016-01-28 | Cleveland Biolabs, Inc. | Flagellin derivatives and uses |
Non-Patent Citations (3)
| Title |
|---|
| CLAUDIA CHIODONI ET AL.: ""Different requirements for α -galactosylceramideand recombinant IL-12 antitumor activity in thetreatment of C-26 colon carcinoma hepatic metastases"", 《EUR. J. IMMUNOL》 * |
| CRAIG M. BRACKETTA ET AL.: ""Toll-like receptor-5 agonist, entolimod, suppresses metastasis and induces immunity by stimulating an NK-dendritic-CD8+ T-cell axis"", 《PNAS》 * |
| 杨常雅: ""131I anti-TLR5 McAb在荷肝癌鼠模型的生物学分布和TLR5激动剂抗肝癌活性研究"", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Li et al. | Astragalus polysacharin inhibits hepatocellular carcinoma-like phenotypes in a murine HCC model through repression of M2 polarization of tumour-associated macrophages | |
| CN113599527B (en) | Application of APOE inhibitor and PD-1 monoclonal antibody in preparation of medicine for treating digestive tract tumor | |
| CN103239464B (en) | Application of icarisid II in preparation of sensitizer for chemotherapic medicine | |
| CN101780066B (en) | Usage of isothiocyanate in preparing medicine for preventing from tumor invasion and metastasis | |
| CN102153657A (en) | IL-24-TAT PTD fusion protein and construction method and application thereof | |
| CN106913571A (en) | A kind of medicine and its application for treating tumour | |
| CN109730983A (en) | Application of the rhapontigenin in preparation treatment medication for treating pyemia | |
| CN107174654A (en) | The new application of interleukin 12 | |
| CN111228287A (en) | Application of epimedium flavone glycoside compound in preparing medicine for treating melanoma | |
| CN106974908A (en) | Pharmaceutical composition and purposes containing hdac inhibitor and IRE1 inhibitor | |
| CN110452162A (en) | A kind of application of chalcone derivative as Fli-1 gene target regulator | |
| CN109675043A (en) | Methionine is in enhanced sensitivity taxol to the application in breast cancer treatment effect | |
| CN103316035A (en) | Use of sodium bicarbonate in preparation of medicines for treating cancer | |
| Cao et al. | A preliminary study on the anticancer efficacy of Caulis spatholobi compound 1802. | |
| CN113663081A (en) | Application of oroxylin and PD-1/PD-L1 inhibitor in preparation of liver cancer treatment drug | |
| CN105663147A (en) | Application of 4-hydroxyl salicylanilide in preparation of anti-tumor drugs | |
| CN110251513A (en) | A kind of indolizine compounds application in preparation of anti-tumor drugs containing pyrazoles | |
| CN107595872B (en) | Pharmaceutical composition for inhibiting prostate cancer stem cells and application thereof | |
| CN104906578A (en) | Application of proton pump inhibitor in preparation of medicine for treating hepatocellular carcinoma | |
| CN106366080A (en) | Anti-melanoma compound and application thereof | |
| CN108309994A (en) | Application of the magnesium isoglycyrrhetate in preparing antineoplastic immune regulation and control medicine | |
| CN109966275A (en) | Quinoid chalcone compound application in preparation of anti-tumor drugs | |
| CN106943400B (en) | Enhance liver cancer cells to the compound and its preparation of CIK cell killing sensibility | |
| CN111388665B (en) | Compound for treating tumor and preparation and application thereof | |
| CN110585435B (en) | Composition with anticancer effect and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170919 |
|
| RJ01 | Rejection of invention patent application after publication |